BeNeLux, France, UK, PortugalFrance

European researchers locate spine growth control genes

02.11.2009

Lissabon/Leicester/Oeiras/Strasbourg/Utrecht - A set of genes that is known to control many aspects of embryonic development is also involved in determining the number of vertebrae in the spine, according to the results of new EU-funded research published in the journal Developmental Cell (Vol. 17, Iss. 4, p. 516-526). In the study, scientists from France, the Netherlands, Portugal and the UK scrutinised the role of Hox genes in spinal development. EU support for the study came from the Cells Into Organs project (Cells Into Organs: functional genomics for development and disease of mesodermal organ systems'), which came to an end earlier this year and received 7.2 million euros in funding from the Sixth Framework Programme thematic area 'Life sciences, genomics and biotechnology for health'.
Hox genes, regulatory genes that play an important role throughout development, can be found throughout the animal kingdom, and are known to help ensure that the right kind of vertebrae grow in the right place. A family of regulatory genes, Cdx, is also known to be involved in the number of vertebrae. When the Cdx genes are disabled, some Hox genes are also rendered inactive, but to date this was assumed to be part of the Hox mechanism controlling vertebrate identity. Normally, switching off the Cdx genes halts the growth of the embryo at the tail end. However, this new research shows that the Hox genes are able to take over and restore growth, and ensure the production of the correct number of somites (and thus vertebrae).
“We now show that the activation of Hox genes is also part of how Cdx genes promote growth of the embryo at its tail end,” explained Moises Mallo from the Instituto Gulbenkian de Ciência in Portugal. “When the relevant Hox genes were activated in the Cdx mouse mutants [i.e. mice lacking the Cdx genes], the embryos recovered and were born with a quite normal vertebral column, proving that the Hox genes were able to compensate for the lack of Cdx. This is a novel role for Hox genes.”
“This paper provides an important addition to a long-standing view on the role of the Hox genes - one of the most-studied genes involved in embryonic development: that it controls not only identity, but also number of vertebrae,” added Dr Mallo. “Although these observations were made in the tail-end region of the embryo, it is very likely that similar mechanisms might be acting to determine the number of segments closer to the head.”

FranceFrance

05.01.2012

Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...

FranceFrance

17.12.2011

Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...

FranceFrance

01.11.2011

Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...

FranceFrance

26.10.2011

Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...

FranceFrance

20.10.2011

Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...

FranceFrance

10.10.2011

Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...

FranceFrance

01.10.2011

Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance

16.09.2011

Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance

09.09.2011

Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/1/article/european-researchers-locate-spine-growth-control-genes.html

Events

All Events

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR303.8%
  • SANTHERA (CH)68.90 CHF102.6%
  • ADDEX (CH)4.06 CHF82.1%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-29.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)68.90 CHF3433.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP769.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)9.69 EUR-69.2%

No liability assumed, Date: 23.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products